Inventor · disambiguated record
Theodore E. Maione
Also filed as: MAIONE THEODORE · MAIONE THEODORE E
17 granted patents·20 pending applications·672 citations·filing 1988–2024
94Inventor score
Files withCYTOGEL PHARMA LLC21REPLIGEN CORP7MAIONE THEODORE E4CLARIANT FINANCE BVI LTD1DOLPHIN DAVID H1
Top patents by PatentIndex Score
37 records- 0198US5112946AModified pf4 compositions and methods of useREPLIGEN CORP·Filed 1989·Granted May 12, 1992·423 cites·18 claims
- 0294US4892941APorphyrinsDOLPHIN DAVID H·Filed 1988·Granted Jan 9, 1990·124 cites·28 claims
- 0386US8940704B2Advantageous salts of μ-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2013·Granted Jan 27, 2015·6 cites·7 claims
- 0484US5077394APorphyrins and uses thereofSANDOZ LTD·Filed 1989·Granted Dec 31, 1991·22 cites·25 claims
- 0583US11324798B2Materials and methods for treatment of inflammationCYTOGEL PHARMA LLC·Filed 2020·Granted May 10, 2022·1 cites·1 claims
- 0683US5086164ANovel methods and compositions for treatment of angiogenic diseasesREPLIGEN CORP·Filed 1989·Granted Feb 4, 1992·30 cites·13 claims
- 0780US10975121B2Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereofCYTOGEL PHARMA LLC·Filed 2018·Granted Apr 13, 2021·1 cites·1 claims
- 0879US5759547AMethods and compositions for treatment of angiogenic diseasesREPLIGEN CORP·Filed 1995·Granted Jun 2, 1998·29 cites·4 claims
- 0979US2023212221A1Novel Therapeutic Uses of Mu-Opiate Receptor PeptidesCYTOGEL PHARMA LLC·Filed 2022·Application pending·0 cites
- 1078US2025074941A1Polymer Agonists of Mu Opioid ReceptorsCYTOGEL PHARMA LLC·Filed 2024·Application pending·0 cites
- 1177US2022324908A1Advantageous salts of mu-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2021·Application pending·0 cites
- 1275US12146002B2Polymer agonists of mu opioid receptorsCYTOGEL PHARMA LLC·Filed 2022·Granted Nov 19, 2024·0 cites·13 claims
- 1375US10441625B2Materials and methods for treatment of inflammationCYTOGEL PHARMA LLC·Filed 2018·Granted Oct 15, 2019·1 cites·2 claims
- 1474US2022249593A1Materials and Methods for Treatment of InflammationCYTOGEL PHARMA LLC·Filed 2022·Application pending·0 cites
- 1571US5284827ASystemic treatment of metastatic cancer with platelet factor 4REPLIGEN CORP·Filed 1990·Granted Feb 8, 1994·22 cites·4 claims
- 1671US2020339628A1Advantageous salts of mu-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2020·Application pending·0 cites
- 1771US2021277057A1Advantageous mu-opiate receptor peptide compoundsCYTOGEL PHARMA LLC·Filed 2021·Application pending·0 cites
- 1868US2020331962A1Novel therapeutic uses of mu-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2020·Application pending·0 cites
- 1967US2011190214A1Advantageous Salts of Mu-Opiate Receptor PeptidesMAIONE THEODORE E·Filed 2008·Application pending·0 cites
- 2067US2011065648A1Advantageous mu-opiate receptor peptide compoundsMAIONE THEODORE E·Filed 2009·Application pending·0 cites
- 2165US2015152137A1Advantageous salts of mu-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2014·Application pending·0 cites
- 2264US11603385B2Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereofCYTOGEL PHARMA LLC·Filed 2020·Granted Mar 14, 2023·0 cites·4 claims
- 2364US2018291060A1Advantageous salts of mu-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2018·Application pending·0 cites
- 2463US12037416B2Polymer agonists of mu opioid receptorsCYTOGEL PHARMA LLC·Filed 2018·Granted Jul 16, 2024·0 cites·10 claims
- 2563US2014329226A1Method for identifying markersSEROPTIX INC·Filed 2014·Application pending·0 cites
- 2662US2019307831A1Materials and methods for treatment of inflammationCYTOGEL PHARMA LLC·Filed 2019·Application pending·0 cites
- 2759US2018282370A1Novel therapeutic uses of mu-opiate receptor peptidesCYTOGEL PHARMA LLC·Filed 2018·Application pending·0 cites
- 2859US2018251490A1Advantageous mu-opiate receptor peptide compoundsCYTOGEL PHARMA LLC·Filed 2018·Application pending·0 cites
- 2958US2015126455A1Novel Therapeutic Uses of Mu-Opiate Receptor PeptidesCYTOGEL PHARMA LLC·Filed 2013·Application pending·0 cites
- 3054US2016264625A1Advantageous mu-opiate receptor peptide compoundsCYTOGEL PHARMA LLC·Filed 2016·Application pending·0 cites
- 3153US5800820AMethods and compositions for treatment of angiogenic diseasesREPLIGEN CORP·Filed 1995·Granted Sep 1, 1998·6 cites·10 claims
- 3251US2008249715A9Method for identifying markersMAIONE THEODORE E·Filed 2004·Application pending·0 cites
- 3351US2011287040A1Materials and methods for treatment of inflammationMAIONE THEODORE E·Filed 2011·Application pending·0 cites
- 3441US2002197600A1Method for determining the presence of infection in an individualFiled 2002·Application pending·0 cites
- 3539US5482923AHeparin neutralization with platelet factor 4 fragmentsREPLIGEN CORP·Filed 1993·Granted Jan 9, 1996·5 cites·18 claims
- 3625US5204321AHeparin neutralization with platelet factor 4REPLIGEN CORP·Filed 1992·Granted Apr 20, 1993·2 cites·19 claims
- 3723US5616473ACloning and expression of ligninasesCLARIANT FINANCE BVI LTD·Filed 1994·Granted Apr 1, 1997·0 cites·16 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →